Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Greece

- PMLiVE

Kite files first CAR-T candidate in Europe

But will need to play catch up in the US, where Novartis has a slight lead

- PMLiVE

Novartis and Bayer among backers for European big data project

The IMI's BigData@Heart programme will target cardiovascular research

- PMLiVE

CHMP backs three immuno-oncology drugs for solid tumours

Roche, MSD and Merck/Pfizer are all on course for new European approvals later this year

- PMLiVE

Race to CGRP migraine drug finish line enters the final straight

US regulator keeps Aimovig ahead of competitors including Lilly’s galcanezumab

- PMLiVE

Alcon’s return to growth gives Novartis ‘options’, says CEO

Sales up 3% to $1.5bn in second quarter for ailing eyecare division

- PMLiVE

Alcon’s return to growth gives Novartis ‘options’, says CEO

Sales up 3% to $1.5bn in second quarter for ailing eyecare division

- PMLiVE

Novartis’ CAR-T clears FDA panel with relative ease

Puts tisagenlecleucel-T on course to be first approved personalised CAR-T therapy

- PMLiVE

Novartis gets first-line approval for Xalkori challenger in EU

Zykadia showed a 45% reduction in the risk of disease progression compared to chemo

- PMLiVE

CV data sets up Novartis’ Ilaris for blockbuster sales

Drug shown to reduce major adverse cardiovascular events

- PMLiVE

Sandoz joins Europe’s MabThera biosimilar push

Novartis’ unit is second company to claim approval in Europe for biosimilar version

EU flag

Medicxi aims to plug funding gap for European biotech

Fund also backed by Novartis, Alphabet’s Verily unit and the EIF

Google’s Verily backs $300m European life sciences fund

The Medicxi fund for drug development firms also attracts support from Novartis

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links